AR105493A1 - Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h - Google Patents
Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132hInfo
- Publication number
- AR105493A1 AR105493A1 ARP160102274A ARP160102274A AR105493A1 AR 105493 A1 AR105493 A1 AR 105493A1 AR P160102274 A ARP160102274 A AR P160102274A AR P160102274 A ARP160102274 A AR P160102274A AR 105493 A1 AR105493 A1 AR 105493A1
- Authority
- AR
- Argentina
- Prior art keywords
- idh1
- muted
- inhibitor
- adduct
- isocitrate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente se relaciona con el aducto ácido (2E)-but-2-enedioico - ácido 3-(2-{[4-(trifluorometoxi)fenil]amino}-1-[(1R,5R)-3,3,5-trimetilciclohexil]-1H-bencimidazol-5-il)propanoico (1:4), métodos para preparar este aducto, composiciones farmacéuticas que comprenden este aducto y también el uso de este aducto para preparar un medicamento o para el tratamiento de una enfermedad.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15178419 | 2015-07-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR105493A1 true AR105493A1 (es) | 2017-10-11 |
Family
ID=53758092
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160102274A AR105493A1 (es) | 2015-07-27 | 2016-07-27 | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h |
Country Status (26)
Country | Link |
---|---|
US (1) | US10344004B2 (es) |
EP (1) | EP3328837B1 (es) |
JP (1) | JP6804516B2 (es) |
KR (1) | KR20180030789A (es) |
CN (1) | CN107810181B (es) |
AR (1) | AR105493A1 (es) |
AU (1) | AU2016300980B2 (es) |
BR (1) | BR112018001534A2 (es) |
CA (1) | CA2993473A1 (es) |
CL (1) | CL2018000249A1 (es) |
CO (1) | CO2018000793A2 (es) |
CR (1) | CR20180053A (es) |
CU (1) | CU20180014A7 (es) |
DO (1) | DOP2018000027A (es) |
EA (1) | EA201890386A1 (es) |
EC (1) | ECSP18006465A (es) |
ES (1) | ES2860693T3 (es) |
HK (1) | HK1252449A1 (es) |
IL (1) | IL256024A (es) |
MX (1) | MX2018001205A (es) |
NI (1) | NI201800014A (es) |
PE (1) | PE20181038A1 (es) |
SV (1) | SV2018005621A (es) |
TN (1) | TN2018000038A1 (es) |
TW (1) | TW201708193A (es) |
WO (1) | WO2017016992A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2732902T3 (es) | 2014-02-11 | 2019-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Bencimidazol-2-aminas como inhibidores de MIDH1 |
KR20160115991A (ko) | 2014-02-11 | 2016-10-06 | 바이엘 파마 악티엔게젤샤프트 | Midh1 억제제로서의 벤즈이미다졸-2-아민 |
EP3209660B1 (en) | 2014-10-23 | 2020-06-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors |
JP6830909B2 (ja) | 2015-06-08 | 2021-02-17 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | mIDH1阻害剤としてのN−メンチルベンズイミダゾール |
EP3319945B1 (en) | 2015-07-07 | 2021-04-28 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors |
EP3322694B1 (en) | 2015-07-16 | 2020-02-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
EP3121166A1 (en) | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
TW201718513A (zh) | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | 製備經取代之3-(2-苯胺-1-環己基-1h-苯并咪唑-5-基)丙酸衍生物之方法 |
WO2019015672A1 (zh) * | 2017-07-21 | 2019-01-24 | 南京明德新药研发股份有限公司 | 吡啶并咪唑类化合物及其应用 |
WO2019025256A1 (en) | 2017-08-01 | 2019-02-07 | Bayer Aktiengesellschaft | COMBINATION OF MIDH1 INHIBITORS AND DNA HYPOMETHYLATION (AHM) AGENTS |
CN108948205B (zh) * | 2018-07-13 | 2021-09-28 | 北京金岱生物科技有限公司 | 抗idh1r132h单克隆抗体及其应用 |
TWI760017B (zh) * | 2019-12-23 | 2022-04-01 | 大陸商昆藥集團股份有限公司 | 一種idh1突變體抑制劑的鹽型、晶型及其製備方法 |
AU2021311539A1 (en) | 2020-07-21 | 2023-02-09 | Daiichi Sankyo Company, Limited | Combination drug of temozolomide and inhibitor of mutated IDH1 enzyme |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010151441A1 (en) * | 2009-06-23 | 2010-12-29 | Translational Genomics Research Institute | Benzamide derivatives |
EA024026B1 (ru) * | 2010-11-25 | 2016-08-31 | Рациофарм Гмбх | Новые соли и полиморфные формы афатиниба |
WO2013046136A1 (en) * | 2011-09-27 | 2013-04-04 | Novartis Ag | 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh |
KR20160115991A (ko) | 2014-02-11 | 2016-10-06 | 바이엘 파마 악티엔게젤샤프트 | Midh1 억제제로서의 벤즈이미다졸-2-아민 |
ES2732902T3 (es) | 2014-02-11 | 2019-11-26 | Deutsches Krebsforschungszentrum Stiftung Des Oeffentlichen Rechts | Bencimidazol-2-aminas como inhibidores de MIDH1 |
CN107108522B (zh) * | 2014-10-23 | 2020-12-01 | 德国癌症研究中心 | 作为mIDH1抑制剂的苯并咪唑-2-胺 |
EP3209660B1 (en) | 2014-10-23 | 2020-06-17 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | 1-cyclohexyl-2-phenylaminobenzimidazoles as midh1 inhibitors for the treatment of tumors |
JP6830909B2 (ja) * | 2015-06-08 | 2021-02-17 | ドイチェス クレープスフォルシュングスツェントルム シュティフトゥング デス エッフェントリッヒェン レヒツ | mIDH1阻害剤としてのN−メンチルベンズイミダゾール |
EP3319945B1 (en) | 2015-07-07 | 2021-04-28 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | 2-aryl- and 2-arylalkyl-benzimidazoles as midh1 inhibitors |
EP3322694B1 (en) | 2015-07-16 | 2020-02-19 | Bayer Pharma Aktiengesellschaft | 5-hydroxyalkylbenzimidazoles as midh1 inhibitors |
EP3121166A1 (en) | 2015-07-21 | 2017-01-25 | Bayer Pharma Aktiengesellschaft | Fused imidazoles as midh1 inhibitors |
TW201718513A (zh) * | 2015-07-27 | 2017-06-01 | 拜耳製藥公司 | 製備經取代之3-(2-苯胺-1-環己基-1h-苯并咪唑-5-基)丙酸衍生物之方法 |
-
2016
- 2016-07-14 TW TW105122262A patent/TW201708193A/zh unknown
- 2016-07-22 WO PCT/EP2016/067477 patent/WO2017016992A1/en active Application Filing
- 2016-07-22 PE PE2018000133A patent/PE20181038A1/es unknown
- 2016-07-22 EP EP16741332.7A patent/EP3328837B1/en active Active
- 2016-07-22 BR BR112018001534A patent/BR112018001534A2/pt not_active Application Discontinuation
- 2016-07-22 ES ES16741332T patent/ES2860693T3/es active Active
- 2016-07-22 KR KR1020177036977A patent/KR20180030789A/ko unknown
- 2016-07-22 EA EA201890386A patent/EA201890386A1/ru unknown
- 2016-07-22 AU AU2016300980A patent/AU2016300980B2/en not_active Ceased
- 2016-07-22 CU CUP2018000014A patent/CU20180014A7/es unknown
- 2016-07-22 CN CN201680038633.9A patent/CN107810181B/zh active Active
- 2016-07-22 JP JP2018504187A patent/JP6804516B2/ja active Active
- 2016-07-22 CA CA2993473A patent/CA2993473A1/en not_active Abandoned
- 2016-07-22 CR CR20180053A patent/CR20180053A/es unknown
- 2016-07-22 MX MX2018001205A patent/MX2018001205A/es unknown
- 2016-07-22 US US15/748,014 patent/US10344004B2/en not_active Expired - Fee Related
- 2016-07-22 TN TNP/2018/000038A patent/TN2018000038A1/en unknown
- 2016-07-27 AR ARP160102274A patent/AR105493A1/es unknown
-
2017
- 2017-11-30 IL IL256024A patent/IL256024A/en unknown
-
2018
- 2018-01-26 EC ECIEPI20186465A patent/ECSP18006465A/es unknown
- 2018-01-26 NI NI201800014A patent/NI201800014A/es unknown
- 2018-01-26 SV SV2018005621A patent/SV2018005621A/es unknown
- 2018-01-26 CL CL2018000249A patent/CL2018000249A1/es unknown
- 2018-01-26 CO CONC2018/0000793A patent/CO2018000793A2/es unknown
- 2018-01-26 DO DO2018000027A patent/DOP2018000027A/es unknown
- 2018-09-13 HK HK18111750.7A patent/HK1252449A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
ECSP18006465A (es) | 2018-04-30 |
KR20180030789A (ko) | 2018-03-26 |
AU2016300980A1 (en) | 2017-12-21 |
EP3328837A1 (en) | 2018-06-06 |
AU2016300980B2 (en) | 2020-12-24 |
CA2993473A1 (en) | 2017-02-02 |
MX2018001205A (es) | 2018-04-24 |
US20180222870A1 (en) | 2018-08-09 |
JP2018521095A (ja) | 2018-08-02 |
CO2018000793A2 (es) | 2018-05-10 |
JP6804516B2 (ja) | 2020-12-23 |
HK1252449A1 (zh) | 2019-05-24 |
EA201890386A1 (ru) | 2018-08-31 |
TN2018000038A1 (en) | 2019-07-08 |
SV2018005621A (es) | 2018-12-05 |
ES2860693T3 (es) | 2021-10-05 |
WO2017016992A1 (en) | 2017-02-02 |
NI201800014A (es) | 2018-09-06 |
US10344004B2 (en) | 2019-07-09 |
DOP2018000027A (es) | 2018-02-28 |
CU20180014A7 (es) | 2018-06-05 |
IL256024A (en) | 2018-01-31 |
EP3328837B1 (en) | 2021-01-06 |
CR20180053A (es) | 2018-03-20 |
PE20181038A1 (es) | 2018-07-03 |
CN107810181A (zh) | 2018-03-16 |
CN107810181B (zh) | 2021-06-22 |
TW201708193A (zh) | 2017-03-01 |
CL2018000249A1 (es) | 2018-07-06 |
BR112018001534A2 (pt) | 2018-09-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR105493A1 (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h | |
CL2023000767A1 (es) | Métodos para reducir el riesgo de eventos cardiovasculares en un sujeto. | |
CL2018000318A1 (es) | Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925) | |
BR112016020199A8 (pt) | composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso | |
CR20170242A (es) | Benzamidas sustituidas copn 1,3-tiazol-2-ilo | |
EA201790398A1 (ru) | Способы лечения заболевания печени | |
WO2015123423A3 (en) | Methods for treating patients with hypercholesterolemia that is not adequately controlled by moderate-dose statin therapy | |
UY35933A (es) | Composiciones farmacéuticas que comprenden azd9291 | |
BR112016015449A8 (pt) | compostos inibidores terapêuticos, composição farmacêutica os compreendendo e uso dos mesmos | |
BR112018005905A2 (pt) | ?composto, composição farmacêutica, métodos para evitar ou tratar uma doença ou condição, lesões de órgão, hepatotoxicidade e fígado gorduroso, e, uso de um composto? | |
BR112016028845A2 (pt) | composto, composição farmacêutica e uso de um composto | |
EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
EA201391018A1 (ru) | Препараты иммуносупрессантов | |
BR112017012406A2 (pt) | formulação com relação fixa de insulina glargina/lixisenatida | |
MX2022001796A (es) | Metodos y composiciones para inhibir los sintomas asociados con la veisalgia. | |
BR112017006425B8 (pt) | Compostos derivados de isoxazol, seus usos, inibidores de isocitrato desidrogenase 1 mutante e da produção de d-2 hidroxiglutamato, agente antitumoral e composição farmacêutica compreendendo os mesmos | |
CO7131387A2 (es) | Composiciones y métodos de polipéptidos-complejo de quelato de oligonucleótido | |
EA201890075A1 (ru) | Инъецируемые фармацевтические композиции лефамулина | |
MY193996A (en) | Tripeptide compound, preparation method therefor, and application thereof | |
EA201691792A1 (ru) | Фармацевтические составы на основе вилдаглиптина | |
CR20160353A (es) | Inhibidor de proteína de transferencia del éster de colesterilo (cetp) y composiciones farmacéuticas que comprenden el inhibidor para uso en el tratamiento o prevención de enfermedades cardiovasculares | |
BR112017024126B8 (pt) | Composições farmacêuticas, composto a micronizado e/ou pelo menos um sal farmaceuticamente aceitável micronizado do composto a e uso dos mesmos | |
MX2017006747A (es) | Amidas de acidos grasos para la prevencion y/o tratamiento de la esteatohepatitis. | |
BR112018005843A2 (pt) | inibidores de calicreína de plasma humano | |
EA201992149A1 (ru) | Комбинация активных ингредиентов, содержащие ее композиции и их применение в лечении саркопении |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |